Article Text
PDF
Abstract
Introduction/Background The approval of poly(ADP-ribose) polymerase inhibitors (PARPi) as first-line maintenance (1LM) provided a new frontline treatment option for patients with advanced ovarian cancer (aOC) in the UK. The objective of this real-world study was to describe patient characteristics and treatment patterns pre- and post-2018 to examine how 1LM PARPi changed the aOC treatment landscape in England.
Methodology This retrospective study used anonymized electronic health record-derived data from the UK Arcturis data set of 4 National Health Service trusts across England. Eligible patients were female adults with newly diagnosed FIGO stage III or IV aOC (ICD-10 code: C56x, C57.0x, or C48x) between 2015 and 2023 with no other active malignancies. Data were stratified by patient diagnosis date at the midpoint of the study period (before vs after 1 January 2018). All analyses were descriptive.
Results Among 2971 records, 654 patients with aOC were eligible per predefined inclusion criteria (mean [SD] age, 66.5 [12.2] years; pre-2018, n=346 [52.9%]; post-2018, n=308 [47.1%]). Whilst both groups were similar demographically, post-2018, more patients had confirmed stage IV disease (29.2% vs 18.2% pre-2018) and high-grade serous histology (86.5% vs 79.5% pre-2018). Treatment patterns pre- and post-2018 are shown (figure 1). Most patients received first-line (1L) systemic anticancer therapies (overall, 84.9%; pre-2018, 85.3%; post-2018, 84.4%), which consisted primarily of platinum-based regimens (551/555; 99.3%). A higher proportion of patients who received 1L treatment received 1LM treatment post-2018 (47.3%) than pre-2018 (24.7%). This increase was driven by greater 1LM PARPi use (pre-2018, <1%; post-2018, 35.0%).
Conclusion This study provided valuable insights on the aOC treatment landscape in England before and after PARPi approvals. Results demonstrated that the introduction of 1LM PARPi modified aOC treatment pathways in England. Relative to patients diagnosed pre-2018, patients diagnosed post-2018 were twice as likely to receive 1LM treatments, driven by increased PARPi use.
Disclosures This study (OneCDP214506) was sponsored by GSK (Waltham, MA, USA).
